贝瑞基因(000710) - 2024 Q2 - 季度业绩预告

Financial Performance Forecast - The company forecasts a net profit attributable to shareholders of between 8 million and 12 million yuan for the first half of 2024, compared to a loss of 95.1078 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 7.5 million and 11.5 million yuan, compared to a loss of 81.8640 million yuan in the previous year[3]. - Basic earnings per share are projected to be between 0.0226 yuan and 0.0339 yuan, while the previous year recorded a loss of 0.2690 yuan per share[3]. Operational Improvements - The company has improved operational quality and effectively controlled costs, resulting in an increase in gross profit margin compared to the same period last year[5]. - The company has strengthened expense control, leading to a decrease in period expenses compared to the previous year[6]. - The loss from the fair value measurement of shares held in Prenetics has decreased compared to the same period last year[6]. Financial Reporting and Risks - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited[4]. - The company emphasizes the importance of the upcoming 2024 semi-annual report for accurate financial data[8]. - Investors are advised to be aware of investment risks associated with the performance forecast[8]. Announcement Details - The announcement was made by the board of directors of Chengdu Berry Genomics Technology Co., Ltd. on July 12, 2024[9].